Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer

  Visterra Appoints Brian Pereira, M.D., as President and Chief Executive

 —Company to Accelerate Product Development based on Novel Antibody Platform
                       focused on Infectious Diseases—

Business Wire

CAMBRIDGE, Mass. -- July 15, 2013

Visterra, Inc., developer of novel medicines to prevent and treat infectious
and other major diseases, today announced the appointment of Brian J. G.
Pereira, M.D., as President and Chief Executive Officer.Dr. Pereira takes on
the role of CEO at a time when Visterra is advancing its product candidates
into human clinical trials for infectious diseases that impact global
health.He is a seasoned biopharmaceutical and healthcare leader with
experience in financing and growing companies, including the clinical
development and commercialization of innovative drug products.

Dr. Pereira has also been appointed to the Board of Directors for Visterra. He
succeeds Steven Brugger, who will be leaving Visterra to pursue other

"We thank Steve Brugger for his many contributions to Visterra. Under his
leadership, we have built a team with extraordinary capabilities, developed a
pipeline of products that have the potential for significant patient impact,
forged a key collaboration with Pfizer, and secured an important strategic
partnership with and equity investment from the Bill & Melinda Gates
Foundation," said Alan Crane, Chairman of Visterra's Board of Directors and
General Partner at Polaris Partners. "We are extremely pleased that Brian
Pereira has become Visterra’s CEO as the company embarks on its next stage of
growth. Brian brings his proven industry leadership with an impressive track
record for managing high-performance teams and building significant company
value, and these skills will augment the expertise of the existing Visterra
team to advance the company’s strategy and product development programs.”

"I am excited to take on the opportunity and grow Visterra as the company
takes the next steps to develop and commercialize innovative therapies for
infectious and other diseases with such broad potential to impact global
health," said Brian J. G. Pereira, President and Chief Executive Officer of
Visterra. "I envision Visterra as a company with the potential to deliver
multiple products from its novel therapeutic platform, and I look forward to
working with the strong team that is in place, so that together we will
accelerate opportunities to develop and commercialize innovative medicines."

Prior to joining Visterra, Dr. Pereira served as the President and CEO of AMAG
Pharmaceuticals, Inc. (NASDAQ: AMAG) from 2006 to 2011 and as its President
from 2005 to 2006. At AMAG, Dr. Pereira played the leadership role in rapidly
creating value, raising four financing rounds at increasing valuations, and
building the clinical development, manufacturing, supply-chain, commercial and
financial infrastructure for AMAG’s iron therapy product for anemia. Prior to
AMAG, he served as the President and CEO of a Tufts Medical Center Physician
Organization from 2001 to 2005, where he was instrumental in restructuring
operations to enable greater financial strength. He also served in earlier
roles at Tufts Medical Center including Interim Chief Operating Officer in
2001, Vice-Chairman for Strategic Development of the Department of Medicine
from 1999-2001, and as a staff physician beginning in 1993.

Dr. Pereira currently serves on the Board of Directors of Biodel, Inc.
(NASDAQ: BIOD), NephroPlus Ltd., The American India Foundation, and Youth That
Care, Inc. He was the Chairman of the Board of the Harvard-MIT Biomedical
Enterprise Program, President of the National Kidney Foundation (USA) from
2002 to 2004 and served on its Board for 10 years. He is an Adjunct Professor
of Medicine at Tufts University School of Medicine, Sackler School of
Biomedical Sciences and Tufts Clinical & Translational Sciences Institute. He
has contributed over 200 published scientific articles and has edited the
leading medical textbook on chronic kidney disease. He received his medical
degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM
(Nephrology) from the Post Graduate Institute, and an MBA from Kellogg
Graduate School of Management at Northwestern University.

About Visterra

Visterra discovers and develops novel antibodies for the prevention and
treatment of infectious and other major diseases. The company’s proprietary
antibody discovery platform generates unique structural information that
identifies novel target epitopes (sites recognized by antibodies) and guides
the design of antibodies which specifically target these epitopes to
effectively combat disease. The company’s lead antibody product candidate,
VIS410, is a broad spectrum monoclonal antibody for the prevention and
treatment of both seasonal and pandemic influenza. The company is building a
proprietary pipeline of novel antibodies in infectious disease, and continuing
to expand its disease area focus through strategic partnerships in infectious
and other diseases. The company announced an antibody discovery collaboration
deal with Pfizer in September, 2012. Visterra was founded based on the
scientific work of Dr. Ram Sasisekharan at MIT, and is currently backed by
Polaris Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates
Foundation, and Omega Funds. For more information please visit


The Yates Network
Kathryn Morris, 845-635-9828
Press spacebar to pause and continue. Press esc to stop.